Cadila completes Phase 2 trial for Covid-19 with Hepatitis C drug

By: |
November 13, 2020 4:50 AM

The company is already working on a Covid-19 vaccine and is in the process of commencing Phase 3 trials by the end of the calendar year.

A single dose therapy will improve compliance and also make it highly affordable for patients.A single dose therapy will improve compliance and also make it highly affordable for patients.

Ahmedabad-based Cadila Healthcare (CHL) On Thursday said it had completed the Phase 2 clinical trial of biological therapy pegylated interferon alpha-2b, PegiHepTM, on Covid-19 patients.

The company is already working on a Covid-19 vaccine and is in the process of commencing Phase 3 trials by the end of the calendar year.

“The study was carried out on 40 patients, and 95% of those who received a single dose of PegiHepTM along with the standard of care (SOC), became virus-free when assessed by RT-PCR test on Day 14, compared with 68% patients who recovered on receiving only standard of care. Of the patients under Phase 2 trials, 16 recovered as early as Day 7 of the treatment,” the company said in a statement.

The study has indicated that Pegylated Interferon alpha-2b could have a beneficial impact on the patient suffering from “moderate” Covid-19 by reducing their viral load and helping in better disease management such as reduced duration of oxygen support, the Zydus group company said. A single dose therapy will improve compliance and also make it highly affordable for patients.

CHL’s managing director Sharvil Patel said Pegylated Interferon alpha-2b has shown the potential to reduce virus titres when given earlier in the disease and the company will like to explore this biological option further.

PegiHep therapy was first approved internationally in 2001 and is also included in WHO’s Essential Medicines List. Cadila Healthcare’s PegiHepTM was originally approved for Hepatitis C and launched in the Indian market in 2011.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Decide on AstraZeneca’s diabetes drug pleas within 15 days, apex court tells Delhi HC
2COVID-19: Delhi records 121 deaths, 4,454 fresh cases
3WHO says $4.3 billion urgently needed for vaccine sharing scheme